目的 探討半夏糖漿聯(lián)合頭孢泊肟酯治療小兒急性支氣管炎的臨床療效。方法 回顧性分析2019年3月—2021年3月在鄭州大學(xué)附屬兒童醫(yī)院進(jìn)行治療的108例急性支氣管炎患兒，根據(jù)用藥差別分為對(duì)照組和治療組，每組各54例。對(duì)照組口服頭孢泊肟酯干混懸劑，每次5 mg/kg，每12 h 1次，每日最大劑量不超過(guò)0.2 g；治療組在對(duì)照組基礎(chǔ)上口服半夏糖漿，3歲以下、5 mL/次，3～6歲、10 mL/次，6歲以上、15 mL/次，3次/d。兩組均治療10 d進(jìn)行效果比較。觀察兩組的臨床療效，比較兩組癥狀改善時(shí)間、相關(guān)評(píng)分和血清學(xué)指標(biāo)。結(jié)果 經(jīng)治療，治療組的總有效率是98.15%，顯著高于對(duì)照組的85.19%（P<0.05）。經(jīng)治療，治療組發(fā)熱、咳嗽、咳痰和肺部啰音臨床癥狀改善時(shí)間明顯短于對(duì)照組（P<0.05）。經(jīng)治療，兩組咳嗽VAS、CARIFS評(píng)分均較治療前顯著降低，但LCQ評(píng)分均顯著提高（P<0.05）；且治療后治療組相關(guān)評(píng)分改善優(yōu)于對(duì)照組（P<0.05）。經(jīng)治療，兩組血清超敏C反應(yīng)蛋白（hs-CRP）、可溶性髓系細(xì)胞觸發(fā)受體-1（sTREM-1）、降鈣素原（PCT）、半胱氨酰白三烯（CysLTs）、白細(xì)胞介素13（IL-13）水平均顯著降低（P<0.05）；且治療后，治療組炎癥介質(zhì)水平顯著低于對(duì)照組（P<0.05）。結(jié)論 半夏糖漿聯(lián)合頭孢泊肟酯治療急性支氣管炎患兒具有較好的臨床療效，不僅可以改善患兒癥狀，還可促進(jìn)機(jī)體促炎因子水平下降，有利于提高患兒生活質(zhì)量，有著良好臨床應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Banxia Syrup combined with cefpodoxime proxetil in treatment of children with acute bronchitis. Methods A retrospective analysis was performed on 108 children with acute bronchitis treated in Children's Hospital affiliated to Zhengzhou University from March 2019 to March 2021, and they were divided into control group and treatment group according to medication difference, with 54 cases in each group. Patients in the control group were po administered with Cefpodoxime Proxetil for Suspension, 5 mg/(kg·time), once every 12 h, and the maximum daily dose should not exceed 0.2 g. Patients in the treatment group were po administered with Banxia Syrup on the basis of the control group, under 3 years old, 5 mL/time, 3 to 6 years old, 10 mL/time, over 6 years old, 15 mL/time, 3 times daily. The two groups were treated for 10 days. The clinical efficacy of the two groups was observed, and the improvement time, correlation score and serological indicators of the two groups were compared. Results After treatment, the total effective rate in treatment group was 98.15%, significantly higher than 85.19% in control group (P < 0.05). After treatment, the improvement time of fever, cough, expectoration and pulmonary rales in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, cough VAS and CARIFS scores in two groups were significantly decreased compared with before treatment, but LCQ scores were significantly increased (P < 0.05). After treatment, the correlation score of the treatment group was better than that of the control group (P< 0.05). After treatment, serum hs-CRP, soluble myeloid triggering receptor-1 (STREM-1), procalcitonin (PCT), cyste-leukotriene (CysLTs) and interleukin 13 (IL-13) levels in two groups were significantly decreased (P < 0.05). After treatment, the level of inflammatory mediators in treatment group was significantly lower than that in control group (P < 0.05). Conclusion Banxia Syrup combined with cefpodoxime proxetil has good clinical effect in treatment of children with acute bronchitis, and can not only improve the symptoms of children, but also promote the decrease of the body's pro-inflammatory factor level, which is conducive to improving the life quality of children, and has good clinical application value.

R974;R985

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（2018020614）